bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2022-67-1-90-107bloodjour-339Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREИнфекционные осложнения и факторы риска их развития после трансплантации аллогенных гемопоэтических стволовых клетокInfectious complications and their contributing risk factors after allogeneic hematopoietic stem cell transplantationhttps://orcid.org/0000-0002-9646-690XАхмедовМ. И.AkhmedovM. I.

Ахмедов Мобил Илгарович, врач-онколог отделения интенсивной высокодозной химиотерапии и трансплантации костного мозга 

125167, Москва

Mobil I. Achmedov, Physician of the Department of Intensive Chemotherapy and BMT 

125167, Moscow

mobilakhmedov@gmail.comhttps://orcid.org/0000-0001-5973-5763КлясоваГ. А.KlyasovaG. A.

Клясова Галина Александровна, доктор медицинских наук, профессор, заведующая лабораторией клинической бактериологии, микологии и антибиотической терапии 

125167, Москва

Galina A. Klyasova, Dr. Sc. (Med.), Professor, Head of the Laboratory of Clinical Microbiology, Mycology and Antibiotic Therapy 

125167, Moscow

klyasova.g@blood.ruhttps://orcid.org/0000-0001-6177-3566ПаровичниковаЕ. Н.ParovichnikovaE. N.

Паровичникова Елена Николаевна, доктор медицинских наук, генеральный директор 

125167, Москва

Elena N. Parovichnikova, Dr. Sc. (Med.), CEO 

125167, Moscow

elenap@blood.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for HematologyRussian Federation20221104202267190107Copyright © Ахмедов М.И., Клясова Г.А., Паровичникова Е.Н., 20222022Ахмедов М.И., Клясова Г.А., Паровичникова Е.Н.Akhmedov M.I., Klyasova G.A., Parovichnikova E.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/339Введение

Введение. Инфекции являются наиболее частыми осложнениями после трансплантации аллогенных гемопоэтических стволовых клеток (алло-ТГСК).

Цель — обзор основных характеристик инфекционных осложнений после алло-ТГСК, а также систематизация основных факторов риска их развития.

Основные сведения

Основные сведения. Помимо основных факторов возникновения инфекционных осложнений, таких как нейтропения, гипогаммаглобулинемия, лимфопения, повреждение слизистых оболочек и развитие реакции «трансплантат против хозяина» (РТПХ), были выделены косвенные факторы, которые связаны с алло-ТГСК, такие как режим кондиционирования, источник трансплантата, тип донора, режим профилактики РТПХ. Представлены основные характеристики инфекционных осложнений после алло-ТГСК с акцентом на наиболее часто регистрируемые, к которым относятся инфекции кровотока. Систематизированы основные факторы риска их развития.

Introduction

Introduction. Infections are among the most common complications after allogeneic hematopoietic stem cell transplantation.

Aim — to provide a literature review on the main characteristics of infectious complications after allogenic hematopoietic stem cell transplantation and risk factors for their development.

Main findings

Main findings. Apart from direct factors such as neutropenia, hypogammaglobulinemia, and lymphopenia, there are indirect transplant-related factors such as conditioning regimen, transplant source, donor type, and graft-versus-host disease prophylaxis associated with higher infectious risk posttransplant. This review also presents the main characteristics of infections after allogeneic hematopoietic stem cell transplantation with a focus on bloodstream infections and provides an overview of the main transplant-related risk factors linked to their development. 

инфекциитрансплантация аллогенных гемопоэтических стволовых клетокфакторы рискаинфекции кровотокаinfectionsallogeneic hematopoietic stem cell transplantationrisk factorsbloodstream infectionsReferencesPassweg J.R., Baldomero H., Chabannon C., et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CART’s come into focus. Bone Marrow Transplant. 2020; 55(8): 1604–13. DOI: 10.1038/s41409-020-0826-4.Passweg J.R., Baldomero H., Chabannon C., et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CART’s come into focus. Bone Marrow Transplant. 2020; 55(8): 1604–13. DOI: 10.1038/s41409-020-0826-4.Савченко В.Г., Любимова Л.С., Паровичникова Е.Н. и др. Трансплантации аллогенных и аутологичных гемопоэтических стволовых клеток при острых лейкозах (итоги 20-летнего опыта). Терапевтический архив. 2007; 79(7): 30–5.Savchenko V.G., Lyubimova L.S., Parovichnikova E.N., et al. Allogeneic and autologous stem cell transplantation for acute leukemias (20-year experience). Terapevticheskiy arkhiv. 2007; 79(7): 30–5 (In Russian).Алянский А.Л., Макаренко О.А., Иванова Н.Е. и др. Развитие регистра неродственных доноров костного мозга в Российской Федерации: опыт НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачeвой. Российский журнал детской гематологии и онкологии. 2016; 3(2): 68–74. DOI: 10.17650/2311-1267-2016-3-2-68-74.Alyanskiy A.L., Makarenko O.A., Ivanova N.E., et al. Development of donor bone marrow registry in Russian Federation: Experience of Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation. Rossiiskiy Journal Detskoy Gematologii I Onkologii. 2016; 3(2): 68–74. DOI: 10.17650/2311-1267-2016-3-2-68-74. (In Russian).Васильева В.А., Кузьмина Л.А., Паровичникова Е.Н. и др. Выполнение трансплантаций аллогенных гемопоэтических стволовых клеток от неродственных доноров из Российского и зарубежного регистров в одном трансплантационном центре. Гематология и трансфузиология. 2020; 65(3): 299–311. DOI: 10.35754/0234-5730-2020-65-3-299-311.Vasilyeva V.A., Kuzmina L.A., Parovichnikova E.N. et al. Unrelated donor transplantations from Russian and foreign registries in a single center. Gematologiya i transfuziologiya. 2020; 65(3): 299–311. DOI: 10.35754/0234-5730-2020-65-3-299-311. (In Russian).Менделеева Л.П., Савченко В.Г., Паровичникова Е.Н. и др. Анализ трансплантационной активности в РФ за 2018 г. (отчет межрегионального регистра). Гематология и трансфузиология. 2020; 65(S1):180.Mendeleeva L.P., Savchenko V.G., Parovichnikova E.N., et al. Transplant activity analysis in Russia in 2018. (Report from interregional registry). Russian Journal of Hematology and Transfusiology (Gematologiya i transfuziologiya). 2020; 65(S1): 180. (In Russian).Wingard J.R., Hsu J., Hiemenz J.W. Hematopoietic stem cell transplantation: An overview of infection risks and epidemiology. Infect Dis Clin North Am. 2010; 24(2): 257–72. DOI: 10.1016/j.idc.2010.01.010.Wingard J.R., Hsu J., Hiemenz J.W. Hematopoietic stem cell transplantation: An overview of infection risks and epidemiology. Infect Dis Clin North Am. 2010; 24(2): 257–72. DOI: 10.1016/j.idc.2010.01.010.Sahin U., Toprak S.K., Atilla P.A., et al. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2016; 22(8): 505–14. DOI: 10.1016/j.jiac.2016.05.006.Sahin U., Toprak S.K., Atilla P.A., et al. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2016; 22(8): 505–14. DOI: 10.1016/j.jiac.2016.05.006.Ustun C., Kim S., Chen M., et al. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Adv. 2019; 3(17): 2525–36. DOI: 10.1182/bloodadvances.2019000226.Ustun C., Kim S., Chen M., et al. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Adv. 2019; 3(17): 2525–36. DOI: 10.1182/bloodadvances.2019000226.Dholaria B., Labopin M., Angelucci E., et al. Improved outcomes of haploidentical hematopoietic cell transplantation with total body irradiation-based myeloablative conditioning in acute lymphoblastic leukemia. Transplant Cell Ther. 2020; 27(2): 171.e1–8. DOI: 10.1016/j.jtct.2020.10.008.Dholaria B., Labopin M., Angelucci E., et al. Improved outcomes of haploidentical hematopoietic cell transplantation with total body irradiation-based myeloablative conditioning in acute lymphoblastic leukemia. Transplant Cell Ther. 2020; 27(2): 171.e1–8. DOI: 10.1016/j.jtct.2020.10.008.Fasslrinner F., Schetelig J., Burchert A., et al. Long-term effi cacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in fi rst complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018; 5(4): e161–9. DOI: 10.1016/S2352-3026(18)30022-X.Fasslrinner F., Schetelig J., Burchert A., et al. Long-term effi cacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in fi rst complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018; 5(4): e161–9. DOI: 10.1016/S2352-3026(18)30022-X.Mohty M., Labopin M., Volin L., et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010; 116(22): 4439–43. DOI: 10.1182/blood-2010-02-266551.Mohty M., Labopin M., Volin L., et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010; 116(22): 4439–43. DOI: 10.1182/blood-2010-02-266551.Anderson D., DeFor T., Burns L., et al. A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant. 2003; 9(1): 52–9. DOI: 10.1053/bbmt.2003.50000.Anderson D., DeFor T., Burns L., et al. A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant. 2003; 9(1): 52–9. DOI: 10.1053/bbmt.2003.50000.Holtick U., Albrecht M., Chemnitz J.M., et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev. 2014; 4: CD010189. DOI: 10.1002/14651858.CD010189.pub2.Holtick U., Albrecht M., Chemnitz J.M., et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev. 2014; 4: CD010189. DOI: 10.1002/14651858.CD010189.pub2.Young J.-A.H., Logan B.R., Wu J., et al. Infections following transplantation of bone marrow or peripheral-blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016; 22(2): 359–70. DOI: 10.1016/j.bbmt.2015.09.013.Young J.-A.H., Logan B.R., Wu J., et al. Infections following transplantation of bone marrow or peripheral-blood stem cells from unrelated donors. Biol Blood Marrow Transplant. 2016; 22(2): 359–70. DOI: 10.1016/j.bbmt.2015.09.013.Parody R., Martino R., Rovira M., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: Comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006; 12(7): 734–48. DOI: 10.1016/j.bbmt.2006.03.007.Parody R., Martino R., Rovira M., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: Comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006; 12(7): 734–48. DOI: 10.1016/j.bbmt.2006.03.007.Ochs L., Shu X.O., Miller J., et al. Late infections after allogeneic bone marrow transplantations: Comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995; 86(10): 3979–86.Ochs L., Shu X.O., Miller J., et al. Late infections after allogeneic bone marrow transplantations: Comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995; 86(10): 3979–86.Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012; 119(17): 3908–16. DOI: 10.1182/blood-2011-09-381699.Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012; 119(17): 3908–16. DOI: 10.1182/blood-2011-09-381699.Chang J., Hsiao M., Blodget E., Akhtari M. Increased risk of 100-day and 1-year infection-related mortality and complications in haploidentical stem cell transplantation. J Blood Med. 2019; 10: 135–43. DOI: 10.2147/JBM.S201073.Chang J., Hsiao M., Blodget E., Akhtari M. Increased risk of 100-day and 1-year infection-related mortality and complications in haploidentical stem cell transplantation. J Blood Med. 2019; 10: 135–43. DOI: 10.2147/JBM.S201073.Ruggeri A., Sun Y., Labopin M., et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017; 102(2): 401–10. DOI: 10.3324/haematol.2016.151779.Ruggeri A., Sun Y., Labopin M., et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica. 2017; 102(2): 401–10. DOI: 10.3324/haematol.2016.151779.Battipaglia G., Labopin M., Kröger N., et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019; 134(11): 892–9. DOI: 10.1182/blood.2019000487.Battipaglia G., Labopin M., Kröger N., et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019; 134(11): 892–9. DOI: 10.1182/blood.2019000487.Samarasinghe S., Clesham K., Iacobelli S., et al. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. Am J Hematol. 2019; 94(1): 80–6. DOI: 10.1002/ajh.25314.Samarasinghe S., Clesham K., Iacobelli S., et al. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. Am J Hematol. 2019; 94(1): 80–6. DOI: 10.1002/ajh.25314.Prezioso L., Manfra I., Bonomini S., et al. Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of GCSF-mobilized peripheral blood progenitor cells. Bone Marrow Transplant. 2019; 54(Suppl 2): 698–702. DOI: 10.1038/s41409-019-0608-z.Prezioso L., Manfra I., Bonomini S., et al. Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of GCSF-mobilized peripheral blood progenitor cells. Bone Marrow Transplant. 2019; 54(Suppl 2): 698–702. DOI: 10.1038/s41409-019-0608-z.Malard F., Labopin M., Cho C., et al. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in fi rst complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol. 2018; 11(1): 127. DOI: 10.1186/s13045-018-0668-3.Malard F., Labopin M., Cho C., et al. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in fi rst complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol. 2018; 11(1): 127. DOI: 10.1186/s13045-018-0668-3.Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18(12): 1835–44. DOI: 10.1016/j.bbmt.2012.07.003.Ciurea S.O., Mulanovich V., Saliba R.M., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18(12): 1835–44. DOI: 10.1016/j.bbmt.2012.07.003.Dettenkofer M., Ebner W., Bertz H., et al. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant. 2003; 31(9): 795–801. DOI: 10.1038/sj.bmt.1703920.Dettenkofer M., Ebner W., Bertz H., et al. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant. 2003; 31(9): 795–801. DOI: 10.1038/sj.bmt.1703920.Mori Y., Yoshimoto G., Nishida R., et al. Gastrointestinal graft-versus-host disease is a risk factor for postengraftment bloodstream infection in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2018; 24(11): 2302–9. DOI: 10.1016/j.bbmt.2018.06.002.Mori Y., Yoshimoto G., Nishida R., et al. Gastrointestinal graft-versus-host disease is a risk factor for postengraftment bloodstream infection in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2018; 24(11): 2302–9. DOI: 10.1016/j.bbmt.2018.06.002.Klastersky J. Concept of empiric therapy with antibiotic combinations. Indications and limits. Am J Med. 1986; 80(5C): 2–12.Klastersky J. Concept of empiric therapy with antibiotic combinations. Indications and limits. Am J Med. 1986; 80(5C): 2–12.EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer. 1990; 26(5): 569–74. DOI: 10.1016/0277-5379(90)90079-9.EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer. 1990; 26(5): 569–74. DOI: 10.1016/0277-5379(90)90079-9.Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998; 41(suppl 4): 13–24. DOI: 10.1093/jac/41.suppl_4.13.Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998; 41(suppl 4): 13–24. DOI: 10.1093/jac/41.suppl_4.13.Клясова Г.А., Сперанская Л.Л., Миронова А.В. и др. Возбудители сепсиса у иммунокомпрометированных больных: структура и проблемы антибиотикорезистентности (результаты многоцентрового исследования). Гематология и трансфузиология. 2007; 52(1): 1–18.Klyasova G.A., Speranskaya L.L., Mironova A.V., et al. Sepsis in immunocompromised patients: Structure and the problem of antibiotic resistance. Gematologiya i transfuziologiya. 2007; 52(1): 1–18. (In Russian).Алгоритмы диагностики и программы лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.; 2018.Savchenko V.G. (ed). Algorithms of diagnostics and program therapy of blood diseases. Moscow; 2018. (In Russian)Mikulska M., Viscoli C., Orasch C., et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014; 68(4): 321–31. DOI: 10.1016/j.jinf.2013.12.006.Mikulska M., Viscoli C., Orasch C., et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014; 68(4): 321–31. DOI: 10.1016/j.jinf.2013.12.006.Averbuch D., Tridello G., Hoek J., et al. Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: Intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017; 65(11): 1819–28. DOI: 10.1093/cid/cix646.Averbuch D., Tridello G., Hoek J., et al. Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: Intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017; 65(11): 1819–28. DOI: 10.1093/cid/cix646.Mikulska M., Raiola A.M., Galaverna F., et al. Pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation: Impact of T cellreplete transplantation from a haploidentical donor. Biol Blood Marrow Transplant. 2018; 24(1): 109–18. DOI: 10.1016/j.bbmt.2017.08.024.Mikulska M., Raiola A.M., Galaverna F., et al. Pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation: Impact of T cellreplete transplantation from a haploidentical donor. Biol Blood Marrow Transplant. 2018; 24(1): 109–18. DOI: 10.1016/j.bbmt.2017.08.024.Stoma I, Karpov I, Milanovich N, et al. Risk factors for mortality in patients with bloodstream infections during the pre-engraftment period after hematopoietic stem cell transplantation. Blood Res. 2016; 51(2): 102–6. DOI: 10.5045/br.2016.51.2.102.Stoma I, Karpov I, Milanovich N, et al. Risk factors for mortality in patients with bloodstream infections during the pre-engraftment period after hematopoietic stem cell transplantation. Blood Res. 2016; 51(2): 102–6. DOI: 10.5045/br.2016.51.2.102.Kikuchi M., Akahoshi Y., Nakano H., et al. Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis. 2015; 17(1): 56–65. DOI: 10.1111/tid.12345.Kikuchi M., Akahoshi Y., Nakano H., et al. Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis. 2015; 17(1): 56–65. DOI: 10.1111/tid.12345.Gudiol C., Garcia-Vidal C., Arnan M., et al. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant. 2014; 49(6): 824–30. DOI: 10.1038/bmt.2014.37.Gudiol C., Garcia-Vidal C., Arnan M., et al. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant. 2014; 49(6): 824–30. DOI: 10.1038/bmt.2014.37.Takagi S., Ogura S., Araoka H., et al. The impact of graft cell source on bloodstream infection in the fi rst 100 days after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021: 56(7): 1625–34. DOI: 10.1038/s41409-021-01229-6.Takagi S., Ogura S., Araoka H., et al. The impact of graft cell source on bloodstream infection in the fi rst 100 days after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021: 56(7): 1625–34. DOI: 10.1038/s41409-021-01229-6.Sanz J., Cano I., González-Barberá E.M., et al. Bloodstream infections in adult patients undergoing cord blood transplantation from unrelated donors after myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2015; 21(4): 755–60. DOI: 10.1016/j.bbmt.2014.12.038.Sanz J., Cano I., González-Barberá E.M., et al. Bloodstream infections in adult patients undergoing cord blood transplantation from unrelated donors after myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2015; 21(4): 755–60. DOI: 10.1016/j.bbmt.2014.12.038.Blennow O., Ljungman P., Sparrelid E., et al. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transplant Infect Dis. 2014; 16(1): 106–14. DOI: 10.1111/tid.12175.Blennow O., Ljungman P., Sparrelid E., et al. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transplant Infect Dis. 2014; 16(1): 106–14. DOI: 10.1111/tid.12175.Macesic N., Morrissey C.O., Cheng A.C., et al. Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period. Transplant Infect Dis. 2014; 16(6): 887–96. DOI: 10.1111/tid.12298.Macesic N., Morrissey C.O., Cheng A.C., et al. Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period. Transplant Infect Dis. 2014; 16(6): 887–96. DOI: 10.1111/tid.12298.Hong J., Moon S.M., Ahn H.K., et al. Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(6): 994–9. DOI: 10.1016/j.bbmt.2013.03.019.Hong J., Moon S.M., Ahn H.K., et al. Comparison of characteristics of bacterial bloodstream infection between adult patients with allogeneic and autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(6): 994–9. DOI: 10.1016/j.bbmt.2013.03.019.Seo S.K., Xiao K., Huang Y.-T., et al. Impact of peri-transplant vancomycin and fl uoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution study. J Infect. 2014; 69(4): 341–51. DOI: 10.1016/j.jinf.2014.06.004.Seo S.K., Xiao K., Huang Y.-T., et al. Impact of peri-transplant vancomycin and fl uoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution study. J Infect. 2014; 69(4): 341–51. DOI: 10.1016/j.jinf.2014.06.004.Bock A.M., Cao Q., Ferrieri P., et al. Bacteremia in blood or marrow transplantation patients: Clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant. 2013; 19(1): 102–8. DOI: 10.1016/j.bbmt.2012.08.016.Bock A.M., Cao Q., Ferrieri P., et al. Bacteremia in blood or marrow transplantation patients: Clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant. 2013; 19(1): 102–8. DOI: 10.1016/j.bbmt.2012.08.016.Busca A., Cavecchia I., Locatelli F., et al. Blood stream infections after allogeneic stem cell transplantation: A single-center experience with the use of levofl oxacin prophylaxis. Transplant Infect Dis. 2012; 14(1): 40–8. DOI: 10.1111/j.1399-3062.2011.00650.x.Busca A., Cavecchia I., Locatelli F., et al. Blood stream infections after allogeneic stem cell transplantation: A single-center experience with the use of levofl oxacin prophylaxis. Transplant Infect Dis. 2012; 14(1): 40–8. DOI: 10.1111/j.1399-3062.2011.00650.x.Liu C.-Y., Lai Y.-C., Huang L.-J., et al. Impact of bloodstream infections on outcome and the infl uence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2011; 46(9): 1231–9. DOI: 10.1038/bmt.2010.286.Liu C.-Y., Lai Y.-C., Huang L.-J., et al. Impact of bloodstream infections on outcome and the infl uence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2011; 46(9): 1231–9. DOI: 10.1038/bmt.2010.286.Ortega M., Rovira M., Almela M., et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005; 84(1): 40–6. DOI: 10.1007/s00277-004-0909-0.Ortega M., Rovira M., Almela M., et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005; 84(1): 40–6. DOI: 10.1007/s00277-004-0909-0.Collin B.A., Leather H.L., Wingard J.R., Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001; 33(7): 947–53. DOI: 10.1086/322604.Collin B.A., Leather H.L., Wingard J.R., Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001; 33(7): 947–53. DOI: 10.1086/322604.Almyroudis N.G., Fuller A., Jakubowski A., et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transplant Infect Dis. 2005; 7(1): 11–7. DOI: 10.1111/j.1399-3062.2005.00088.x.Almyroudis N.G., Fuller A., Jakubowski A., et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transplant Infect Dis. 2005; 7(1): 11–7. DOI: 10.1111/j.1399-3062.2005.00088.x.Averbuch D., Tridello G., Hoek J., et al. Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality. J Infect. 2020; 81(6): 882–94. DOI: 10.1016/j.jinf.2020.11.002.Averbuch D., Tridello G., Hoek J., et al. Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality. J Infect. 2020; 81(6): 882–94. DOI: 10.1016/j.jinf.2020.11.002.Gentile G., Micozzi A., Girmenia C., et al. Pneumonia in allogenic and autologous bone marrow recipients. A retrospective study. Chest. 1993; 104(2): 371–5. DOI: 10.1378/chest.104.2.371.Gentile G., Micozzi A., Girmenia C., et al. Pneumonia in allogenic and autologous bone marrow recipients. A retrospective study. Chest. 1993; 104(2): 371–5. DOI: 10.1378/chest.104.2.371.Aguilar‐Guisado M., Jiménez‐Jambrina M., Espigado I., et al. Pneumonia in allogeneic stem cell transplantation recipients: A multicenter prospective study. Clin Transplantat. 2011; 25(6): E629–38. DOI: 10.1111/j.1399-0012.2011.01495.x.Aguilar‐Guisado M., Jiménez‐Jambrina M., Espigado I., et al. Pneumonia in allogeneic stem cell transplantation recipients: A multicenter prospective study. Clin Transplantat. 2011; 25(6): E629–38. DOI: 10.1111/j.1399-0012.2011.01495.x.Chopra T., Alangaden G.J., Chandrasekar P. Clostridium diffi cile infection in cancer patients and hematopoietic stem cell transplant recipients. Exp Rev Anti-Infective Ther. 2010; 8(10): 1113–9. DOI: 10.1586/eri.10.95.Chopra T., Alangaden G.J., Chandrasekar P. Clostridium diffi cile infection in cancer patients and hematopoietic stem cell transplant recipients. Exp Rev Anti-Infective Ther. 2010; 8(10): 1113–9. DOI: 10.1586/eri.10.95.Bruminhent J. Clostridium diffi cile colonization and disease in patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(9): 1329–34. DOI: 10.1016/j.bbmt.2014.04.026.Bruminhent J. Clostridium diffi cile colonization and disease in patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(9): 1329–34. DOI: 10.1016/j.bbmt.2014.04.026.Balletto E, Mikulska M. Bacterial infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2015; 7(1): e2015045. DOI: 10.4084/mjhid.2015.045.Balletto E, Mikulska M. Bacterial infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2015; 7(1): e2015045. DOI: 10.4084/mjhid.2015.045.Robak K., Zambonelli J., Bilinski J., Basak G.W. Diarrhea after allogeneic stem cell transplantation: Beyond graft-versus-host disease. Eur J Gastroenterol Hepatol. 2017; 29(5): 495–502. DOI: 10.1097MEG.0000000000000833.Robak K., Zambonelli J., Bilinski J., Basak G.W. Diarrhea after allogeneic stem cell transplantation: Beyond graft-versus-host disease. Eur J Gastroenterol Hepatol. 2017; 29(5): 495–502. DOI: 10.1097/MEG.0000000000000833.Schneidewind L., Neumann T., Zimmermann K., et al. Urological complications associated with adult allogeneic stem cell transplantation. Am J Hematol. 2018; 93(1): E3–4. DOI: 10.1002/ajh.24920.Schneidewind L., Neumann T., Zimmermann K., et al. Urological complications associated with adult allogeneic stem cell transplantation. Am J Hematol. 2018; 93(1): E3–4. DOI: 10.1002/ajh.24920.Cesaro S., Dalianis T., Hanssen Rinaldo C., et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2017; 73(1): 12–21. DOI: 10.1093/jac/dkx324.Cesaro S., Dalianis T., Hanssen Rinaldo C., et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2017; 73(1): 12–21. DOI: 10.1093/jac/dkx324.Васильева В.А., Паровичникова Е.Н., Дроков М.Ю. и др. Этиологические особенности геморрагического цистита после трансплантации аллогенных гемопоэтических стволовых клеток. Клиническая микробиология и антимикробная терапия. 2018; 20(3): 232–8. DOI: 10.36488cmac.2018.3.232-238.Vasilieva V.A., Parovichnikova E.N., Drokov M.Yu., et al. Aetiology of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Kliniceskaya Mikrobiologiya i Antimikrobnaya Himioterapiya. 2018; 20(3): 232–8. DOI: 10.36488/cmac.2018.3.232-238. (In Russian).Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009; 15(10): 1143–1238. DOI: 10.1016/j.bbmt.2009.06.019.Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009; 15(10): 1143–1238. DOI: 10.1016/j.bbmt.2009.06.019.

The authors declare that there are no conflicts of interest present.